Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
36 hedge funds and large institutions have $217M invested in Elevation Oncology in 2021 Q2 according to their latest regulatory filings, with 36 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
70.96% more ownership
Funds ownership: 0% → 70.96% (+71%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aisling Capital Management
New York
|
+$35M |
| 2 |
VP
venBio Partners
San Francisco,
California
|
+$32.2M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$24.7M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$24.5M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
+$19.7M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSA
26
Schonfeld Strategic Advisors
New York
| $349K | +$318K | +25,700 | New |
|
27
Qube Research & Technologies (QRT)
London,
United Kingdom
| $329K | +$300K | +24,255 | New |
|
|
WMSA
28
Weiss Multi-Strategy Advisers
New York
| $204K | +$186K | +15,037 | New |
|
|
MS
29
Maven Securities
St Helier,
Jersey
| $204K | +$198K | +16,000 | New |
|
|
PHK
30
Point72 Hong Kong
Hong Kong
| $131K | +$119K | +9,649 | New |
|
31
Northern Trust
Chicago,
Illinois
| $65K | +$59.4K | +4,803 | New |
|
|
WCMNY
32
Westchester Capital Management (New York)
Valhalla,
New York
| $14K | +$12.4K | +1,000 | New |
|
33
UBS Group
Zurich,
Switzerland
| $14K | +$12.9K | +1,045 | New |
|
|
OCM
34
Ovata Capital Management
Hong Kong
| $7K | +$6.18K | +500 | New |
|
|
SPIA
35
Steward Partners Investment Advisory
New York
| $7K | +$6.18K | +500 | New |
|
|
CSS
36
Cubist Systematic Strategies
Stamford,
Connecticut
| $1K | +$1.24K | +100 | New |
|
ELEV Hedge Fund Activity: Q2 2021 in Review
36 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q2 2021, worth a combined $217M.
Buyers outnumbered sellers: 36 funds opened new ELEV positions and 0 closed out — a net gain of 36 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Aisling Capital Management, opening a new position worth an estimated $35M.
- 36 institutional investors held Elevation Oncology (ELEV) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $217M of Elevation Oncology stock for Q2 2021.
- 36 funds opened new Elevation Oncology positions in Q2 2021 and 0 closed out, a net change of +36 holders.
- The largest Elevation Oncology buyer in Q2 2021 was Aisling Capital Management, an estimated $35M added.
Based on aggregated 13F filings for Q2 2021.